Want to see PETV full AI Analyst Report?
PETV Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EST
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.60 - $1.69
Previous CloseN/A
Volume249.00
Average Volume (3M)21.60K
Market Cap
$31.54M
Enterprise Value$21.20M
Total Cash (Recent Filing)$200.78K
Total Debt (Recent Filing)$376.16K
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding37,594,246
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)9.60
Price to Sales (P/S)18.49
P/FCF Ratio-3.45
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue18.57
Enterprise Value/Gross Profit28.09
Enterprise Value/Ebitda-2.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Health Canada Device RecognitionRegulatory recognition by Health Canada creates a durable commercial beachhead in Canada, expanding addressable market exposure into a veterinary market growing ~6.8% CAGR. Device approval reduces regulatory friction for clinics and distributors, supporting multi-year sales growth and credibility among veterinary customers.
Exclusive AI SaaS Platform (PetVivo.ai)A high-margin, scalable B2B SaaS offering with exclusive licensing creates recurring revenue potential and cross-sell synergies with Spryng. Lower CAC materially improves unit economics, while proprietary diagnostics and persistent patient memory support a durable competitive advantage and monetizable data streams over many quarters.
Acquisition Expands Biomaterials IPAdding PBM's piezoelectric biomaterials and IP broadens the product pipeline and opens new regulatory and commercial pathways in regenerative medicine. This structural R&D and IP expansion can enable licensing, platform monetization, and longer-term entry into adjacent human and veterinary markets, strengthening the firm's technological moat.
Bears Say
Persistent Cash BurnConsistent negative operating cash flow (~-$6.1M in 2026) is a structural financing challenge: it erodes runway, forces repeated capital raises, and constrains investments in sales, marketing, and R&D. Without sustained positive OCF, commercialization and product development timelines face recurring funding risk.
Large Ongoing Net LossesVery large losses relative to revenue indicate the business remains far from break-even. High fixed costs, impairments and widening net loss undermine internal cash generation and make self-funded scaling unlikely. Persistent negative profitability raises dilution risk and limits strategic optionality over multiple quarters.
Modest Liquidity CushionAlthough liabilities fell, available working capital (~$482.6k) and modest current assets leave limited runway to execute launches, complete acquisitions, or scale PetVivo.ai. Dependence on staged private placements and financing contingencies creates execution risk and potential timing delays for strategic initiatives.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.60 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $31.54M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Jun 29, 2026. The company reported -$0.088 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.088.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 37,594,246 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.088 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PetVivo Holdings
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
PETV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mix of meaningful strategic and technological progress (AI platform milestones, exclusive AI partnership, Health Canada device recognition, PBM acquisition, strong reductions in liabilities) alongside notable near-term financial challenges (small absolute revenues with only 1% growth, a material gross margin decline driven by low-margin PrecisePRP sales, a $1M impairment, and a $10.5M net loss and cash burn). Operational and product milestones provide a positive long-term narrative, but the company faces short-term execution, profitability, and liquidity risks that balance the positive developments.View all PETV earnings summariesTechnical Analysis
Ownership Overview
39.35% Insiders
0.34% Other Institutional Investors
60.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---